Abpro Holdings Inc. and Celltrion, Inc. have received U.S. FDA clearance for the Investigational New Drug $(IND)$ application of their lead multispecific antibody cancer candidate, ABP-102 / CT-P72. This regulatory approval enables the initiation of a Phase 1 clinical trial targeting HER2-positive solid tumors, with the study anticipated to begin in the first half of 2026. The trial, led by Celltrion, will assess the safety, tolerability, pharmacokinetics, and preliminary efficacy of the therapy as part of a global collaboration between the two companies.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Abpro Holdings Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: GNW9620490-en) on January 06, 2026, and is solely responsible for the information contained therein.